Imunon closed at $0.91 on Nov 4, up 0.78%, 79.3% below its 52-week closing high. Volume of 22.1K shares was 0.18× its 20-day average (below normal).
Split-adjusted performance: -19.0% over one month, -66.5% over six months, -79.3% over one year.
Short interest was 62.4K shares at the Oct 15 settlement, down 64.0% from the prior report (1.2% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IMNNImunon | $0.9070 | +0.78% | −66.5% | — | — | — | $5.1M | |
| SKYESkye Bioscience | $1.14 | −6.56% | −83.3% | — | — | — | $5.0M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
| PCSAProcessa Pharmaceuticals | $1.94 | −0.26% | −29.6% | — | — | — | $5.4M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
| PULMPulmatrix | $1.52 | +14.29% | +11.8% | — | — | — | $5.6M | Compare |
| SCNXScienture Holdings | $3.42 | −0.87% | −65.0% | — | −821.3% | — | $5.6M | Compare |
| ACXPAcurx Pharmaceuticals | $1.03 | +0.98% | −50.7% | — | — | — | $5.6M | Compare |
| TCRTAlaunos Therapeutics | $1.80 | −3.23% | −31.6% | — | — | — | $4.6M | Compare |
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
